The Polynucleotide Is Encapsidated Within A Virus Or Viral Coat Patents (Class 435/456)
-
Patent number: 7906111Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.Type: GrantFiled: September 30, 2004Date of Patent: March 15, 2011Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
-
Patent number: 7906113Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: GrantFiled: October 25, 2006Date of Patent: March 15, 2011Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Publication number: 20110059531Abstract: The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector. The methods can be used to express doubles stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, which are capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos, embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated.Type: ApplicationFiled: June 7, 2010Publication date: March 10, 2011Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: CARLOS LOIS-CABALLE, DAVID BALTIMORE, XIAO-FENG QIN
-
Publication number: 20110052585Abstract: Fusion proteins including an IL-17 receptor with a multimerization domain, or an IL-23 receptor and a multimerization domain, and recombinant viral vectors encoding such fusions, are described. The fusion proteins and vectors encoding such fusions, alone or in combination, can be used in methods for modulating the IL-17 and IL-23 signaling pathways and for treating or preventing diseases mediated by interleukin-17 and interleukin-23, such as immune-related and inflammatory diseases.Type: ApplicationFiled: March 25, 2010Publication date: March 3, 2011Applicant: GENZYME CORPORATIONInventors: Abraham Scaria, Gary White
-
Patent number: 7888121Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.Type: GrantFiled: August 6, 2004Date of Patent: February 15, 2011Assignee: Sangamo Biosciences, Inc.Inventors: Fyodor Urnov, Michael C. Holmes, Jeffrey C. Miller, Carl O. Pabo
-
Patent number: 7871819Abstract: The invention provides a recombinant vector comprising an ovine adenovirus genome and a sequence encoding a heterologous polypeptide, wherein the sequence encoding the heterologous polypeptide is inserted between E4 and E3 transcription units of the ovine adenovirus genome.Type: GrantFiled: December 20, 2005Date of Patent: January 18, 2011Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Peter L. Molloy, Fujiko Watt, Gerry Both
-
Patent number: 7867484Abstract: The present invention is based on the finding that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. In some embodiments, a substitution of a single amino acid that is unique to the AAV6 capsid (Lys-531) among other AAVs that have been characterized to date can confer one or more desirable properties to other AAVs.Type: GrantFiled: January 26, 2007Date of Patent: January 11, 2011Assignee: University of North Carolina at Chapel HillInventors: Richard Jude Samulski, Zhijian Wu, Aravind Asokan
-
Publication number: 20100325746Abstract: Disclosed herein are sequences, molecules and methods used to suppress the expression of HD genes encoding for huntingtin protein in primates including Macaca mulatta and Homo sapiens. These sequences, molecules and methods aid in the study of the pathogenesis of HD and can also provide a treatment for this disease by reducing HD mRNA without causing death, locomotor impairment or cellular alterations of the Macaca mulatta and Homo sapiens.Type: ApplicationFiled: August 9, 2006Publication date: December 23, 2010Inventors: William F. Kaemmerer, Michael D. Kaytor
-
Publication number: 20100323383Abstract: The present invention is directed to an in vitro method for promoting differentiation and proliferation of human T helper lymphocytes that express IL17 (Th-IL17+ cells). The instant method may be used to generate a population of human T helper lymphocytes that express IL 17 (Th-IL 17+ cells) in vitro. Methods for screening to identify agents capable of modulating Th-IL17+ cell differentiation are also encompassed by the present invention. Isolated, pure populations of homogeneous Th-IL17+ cells that do not express cellular markers characteristic of Th1, Th2, or Treg cells are also encompassed herein.Type: ApplicationFiled: April 15, 2009Publication date: December 23, 2010Inventors: Nicolas Manel, Dan R. Littman
-
Publication number: 20100316701Abstract: The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.Type: ApplicationFiled: November 14, 2008Publication date: December 16, 2010Applicant: San Diego State University Foundation, dba San Diego State University Research FoundationInventors: Mark A. Sussman, John A. Muraski
-
Publication number: 20100311171Abstract: Stem cell reprogramming genes cloned into a single sustained expression-type Sendai viral vector are shown to reprogram differentiated somatic cells into induced pluripotent stem (iPS) cells without integration of vector sequences into the host cell's genome. The genes are transduced into normal differentiated somatic cells via infection with recombinant Sendai virus. After expression of the reprogramming genes and subsequent induction of pluripotency, the vector genome RNA including the reprogramming genes is removed from the cell to establish an iPS cell that is genetically identical to the parent somatic differentiated cell thus reducing the risk of tumorigenic transformation caused by random integration of vector sequences into the host genome. The method promises to provide safe, autologous iPS cells that can be used for human cell replacement and regeneration therapeutic applications.Type: ApplicationFiled: June 2, 2010Publication date: December 9, 2010Applicant: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Mahito NAKANISHI, Ken NISHIMURA, Manami OHTAKA, Masayuki SANO
-
Patent number: 7846428Abstract: The present invention relates to recombinant vectors expressing the BMP-7 polypeptide in host cells and to pharmaceutical compositions comprising such recombinant vectors. The invention also encompasses methods for prevention and/or treatment of osteoarthritis in mammals, advantageously in humans, dogs, horses and cats, by intra-articular administration of the recombinant vectors and pharmaceutical compositions of the invention.Type: GrantFiled: October 5, 2007Date of Patent: December 7, 2010Assignee: Merial LimitedInventor: Laurent Bernard Fisher
-
Patent number: 7846454Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.Type: GrantFiled: April 9, 2007Date of Patent: December 7, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Masayuki Yanagi, Jens Bukh, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 7846729Abstract: Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.Type: GrantFiled: August 6, 2007Date of Patent: December 7, 2010Assignee: Genzyme CorporationInventor: Barrie J. Carter
-
Publication number: 20100297084Abstract: This invention provides methods for transducing a ciliated cell with a recombinant serotype 2 adeno-associated virus (AAV) vector. Additionally, the invention provides methods of treating diseases associated with a mutated gene by transducing a ciliated cell with a recombinant serotype 2 AAV vector containing a corrective transgene.Type: ApplicationFiled: May 30, 2008Publication date: November 25, 2010Inventors: Jean Bennett, Joshua Lipschutz
-
Patent number: 7838207Abstract: The present invention concerns the development of a cell-based assay system having improved sensitivity to HCV NS3 protease activity when compared to known assays, which is useful for screening test compounds capable of modulating (particularly inhibiting) HCV NS3 protease activity. This system provides a first construct comprising a transactivator domain joined downstream of the NS3-5 domains of HCV under the control of a non-cytopathic viral promoter system. A second construct is also provided that comprises a reporter gene under the control of an operator sensitive to the binding of the transactivator. The NS3-5 domains encodes the NS3 polyprotein which comprises: the NS3 protease, followed by the NS4A co-factor, the NS4B and NS5A proteins (including any derivative, variant or fragment thereof, terminated by the NS5B protein (including any derivative, variant or fragment thereof) sufficient to constitute a NS5A/5B cleavage site.Type: GrantFiled: May 27, 2005Date of Patent: November 23, 2010Assignee: Boehringer Ingelheim Canada Ltd.Inventors: Charles Pellerin, Daniel Lamarre
-
Publication number: 20100279416Abstract: The invention relates to a method for introducing changes into a eukaryotic genome in vivo wherein the HPV genome, which comprises HPV replication origin sequence, is used together with HPV early proteins in order to achieve DNA replication in vivo. There is also disclosed a kit for in vivo amplification, excision, translocation and/or inversion of a DNA sequence, which comprises a vector carrying HPV genome or a part of HPV genome including HPV replication origin sequence, and expression vector or vectors encoding HPV early proteins.Type: ApplicationFiled: March 27, 2008Publication date: November 4, 2010Inventors: Mart Ustav, Ene Ustav, Meelis Kadaja, Alina Sumerina
-
Publication number: 20100273265Abstract: The present invention provides a medicine, comprising (a) an Otx2 protein or its partial peptide, or a salt thereof, or (b) a DNA or an RNA encoding an Otx2 protein or its partial peptide. The present medicine is useful as an agent for preventing, treating or suppressing progression of a retinal disease including retinal degeneration. In addition, the present medicine is useful, for example, as an agent for inducing differentiation from a retinal stem cell into a retinal photoreceptor cell, in the transplantation of a cell into the retina of patients suffering from retinal diseases.Type: ApplicationFiled: April 26, 2010Publication date: October 28, 2010Inventor: Takahisa Furukawa
-
Patent number: 7820440Abstract: The invention relates to methods and means for producing adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: May 7, 2007Date of Patent: October 26, 2010Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Patent number: 7820441Abstract: The present invention relates to methods and compositions for the production of viral vectors. In particular, the present invention provides methods and compositions for faster, higher titer and higher purity production of viral vectors (e.g. adenoviral vectors). In some embodiments, the present invention provides gutted and helper viruses with identical or similar termini. In other embodiments, the present invention provides terminal protein linked adenoviral DNA. In certain embodiments, the present invention provides template extended adenoviral DNA.Type: GrantFiled: September 21, 2001Date of Patent: October 26, 2010Assignee: The Regents of the University of MichiganInventors: Jeffrey S. Chamberlain, Dennis J. Hartigan-O'Connor
-
Publication number: 20100267146Abstract: In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.Type: ApplicationFiled: April 28, 2010Publication date: October 21, 2010Applicants: CALIFORNIA INSTITUTE OF TECHNOLOGY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Carlos Lois-Caballe, David Baltimore, Xiao-Feng Qin, Irvin S.Y. Chen, Dong Sung An
-
Publication number: 20100267145Abstract: An immunocompetent cell expressing an anti-CD38 antibody on its surface through genetic introduction of a DNA coding for part of the anti-CD38 antibody; and a method of producing an immunocompetent cell expressing the antibody on its cell surface, which includes amplifying a cDNA using the mRNA coding for part of the anti-CD38 antibody isolated from a hybridoma, inserting the amplified cDNA into a retroviral vector, transfecting the vector into a packaging cell to produce a packaging cell capable of producing an anti-CD38 antibody expressing-retroviral particle, and infecting a human immunocompetent cell with the retroviral particle released from the packaging cell.Type: ApplicationFiled: June 5, 2007Publication date: October 21, 2010Applicant: Hiroshima UniversityInventor: Keichiro Mihara
-
Publication number: 20100260731Abstract: The invention relates to a method for propagating or concentrating primary cells without tumorous characteristics and to the subsequent use thereof.Type: ApplicationFiled: September 3, 2008Publication date: October 14, 2010Inventors: Adrianus J.C.M. Braspenning, Stefan Holder, Heiner Kupper
-
Publication number: 20100254945Abstract: Disclosed herein is a double stranded siRNA molecule that inhibits production of a respiratory virus, wherein each strand of said siRNA molecule is about 15 to about 50 nucleotides, and wherein one strand of said siRNA molecule comprises a nucleic acid sequence identical to a conserved site, or a variant thereof, within the nucleic acid sequence of the respiratory virus, and uses thereof.Type: ApplicationFiled: April 7, 2006Publication date: October 7, 2010Applicant: NASTECH PHARMACEUTICAL COMPANY INC.Inventors: Qing Ge, Mukesh Kumar, James Anthony McSwiggen
-
Patent number: 7807145Abstract: The present invention relates to methods of inducing neuronal production in the brain, recruiting neurons to the brain, and treating a neurodegenerative condition by providing a nucleic acid construct encoding a neurotrophic factor, and injecting the nucleic acid construct intraventricularly into a subject's brain.Type: GrantFiled: April 3, 2006Date of Patent: October 5, 2010Assignee: Cornell Research Foundation, Inc.Inventors: Steven A. Goldman, Abdellatif Benraiss
-
Patent number: 7807147Abstract: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.Type: GrantFiled: October 30, 2007Date of Patent: October 5, 2010Assignee: New York UniversityInventor: Daniel Meruelo
-
Publication number: 20100247486Abstract: It is intended to provide a virus vector by which an exogenous nucleotide sequence can be inserted and easily transferred into a mammalian host cell and a gene encoded by the exogenous nucleotide sequence can be expressed in the host cell, and which has a low risk of pathogenicity and is appropriately usable in gene therapy of mammals. Namely, a recombinant vector originating in HHV-6 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U5, U6, U7, U8, U24, and U25 regions of HHV-6; or a recombinant vector originating in HHV-7 which has an exogenous nucleotide sequence in a portion corresponding to at least one region selected from the group consisting of U2, U3, U4, U7, U8, U24, U24a, and U25 regions of HHV-7.Type: ApplicationFiled: August 30, 2004Publication date: September 30, 2010Applicant: Virus Ikagaku Kenkyusho Inc.Inventor: Kazuhiro Kondo
-
Patent number: 7803365Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.Type: GrantFiled: March 13, 2007Date of Patent: September 28, 2010Assignee: Biovec, LLCInventors: Lakshman R. Sehgal, Jonathan Wong
-
Patent number: 7803622Abstract: The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention also provides a composition comprising at least two adeno-associated virus vectors.Type: GrantFiled: February 15, 2005Date of Patent: September 28, 2010Assignee: University of Iowa Research FoundationInventors: John F. Engelhardt, Dongsheng Duan
-
Publication number: 20100233758Abstract: Provided are an isolated protein derived from an N-terminal of HveA/HVEM and having activity of increasing the cell infectivity of herpes simplex virus (HSV) and use thereof.Type: ApplicationFiled: March 16, 2009Publication date: September 16, 2010Applicant: KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCESInventors: Hee Chung Kwon, Hyun Jung Baek, Kee Ho Lee, Masahide Kuroki
-
Patent number: 7794703Abstract: A method for production and delivery of a protein in vivo is described. The method includes steps of inserting a promoter and a gene encoding a protein in a vector, collecting an amount of host cells from a mammal, treating the host cells in vitro with the vector, then introducing the treated cells back to the mammal. In vivo, the treated host cells produce red blood cells and the protein which is contained in the red blood cells. The protein is released into peripheral blood of the mammal through a natural or an induced rupture of the red blood cells to supply the protein to the body.Type: GrantFiled: December 9, 2009Date of Patent: September 14, 2010Inventor: Hai Xing Chen
-
Patent number: 7795032Abstract: Terminal differentiated cells are proliferated by introducing a cyclin and a cyclin dependent kinase into the nucleus of terminal differentiated cells, and then cultivating or holding the cells. A method for proliferating terminal differentiated cells comprising adding a nucleotide sequence coding for a nuclear localization signal to at least one of a cyclin gene and a cyclin dependent kinase gene, and introducing each of the genes to terminal differentiated cells in vitro, and then cultivating the cells, or introducing each of the genes directly to terminal differentiated cells in vivo is provided. The cyclin is a cyclin that can activate CDK4 or CDK6, and the cyclin dependent kinase is a cyclin dependent kinase that is activated by D-type cyclin. The invention also provides a recombinant vector used for such a method or a pharmaceutical composition comprising the vector.Type: GrantFiled: November 17, 2003Date of Patent: September 14, 2010Inventors: Masaaki Ikeda, Mimi Adachi
-
Patent number: 7790154Abstract: The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the invention. Methods of administering these reagents to a cell or subject are also described. Preferably, the parvovirus capsid is an AAV capsid. It is further preferred that the vector genome comprises AAV terminal repeat sequences.Type: GrantFiled: January 19, 2007Date of Patent: September 7, 2010Assignee: The University of North Carolina at Chapel HillInventors: Richard Jude Samulski, Douglas M. McCarty
-
Patent number: 7790419Abstract: A viral vector production system is provided which system comprises: (i) a viral genome comprising at least one first nucleotide sequence encoding a gene product capable of binding to and effecting the cleavage, directly or indirectly, of a second nucleotide sequence, or transcription product thereof, encoding a viral polypeptide required for the assembly of viral particles; (ii) a third nucleotide sequence encoding said viral polypeptide required for the assembly of the viral genome into viral particles, which third nucleotide sequence has a different nucleotide sequence to the second nucleotide sequence such that said third nucleotide sequence, or transcription product thereof, is resistant to cleavage directed by said gene product. The viral vector production system may be used to produce viral particles for use in treating or preventing viral infection.Type: GrantFiled: January 27, 2003Date of Patent: September 7, 2010Assignee: Oxford Biomedica (UK) Ltd.Inventors: Alan John Kingsman, Kyriacos Mitrophanous, Narry Kim
-
Patent number: 7790445Abstract: The present invention relates to a polypeptide possessing a CDase activity, characterized in that it is derived from a native CDase by addition of an amino acid sequence with the proviso that said polypeptide has no UPRtase or Thymidine Kinase activity.Type: GrantFiled: June 29, 2004Date of Patent: September 7, 2010Assignee: Transgene S.A.Inventor: Philippe Erbs
-
Patent number: 7790155Abstract: The present invention provides novel compositions containing a calbindin-D28k therapeutic element, which is involved in the regulation of apoptosis, and may be administered for the prevention of an abnormal apoptosis response in cells. In particular the compositions and methods of the present invention may be used for the prevention or induction of apoptosis in such cells types as osteoblasts and osteocytes. Specifically, the compositions and methods of the present invention are useful for the prevention of diseases associated with glucocorticoid induced cell death. Specifically, the compositions and methods of the present invention may be useful in the prevention of glucocorticoid induced cell death in osteoblasts and the treatment of such conditions as glucocorticoid induced osteoporosis.Type: GrantFiled: July 8, 2005Date of Patent: September 7, 2010Assignee: University of Medicine and Dentistry of New JerseyInventors: Sylvia Christakos, Yan Liu, Teresita Bellido
-
Patent number: 7785886Abstract: The invention features ABC1 nucleic acids and polypeptides for the diagnosis and treatment of abnormal cholesterol regulation. The invention also features methods for identifying compounds for modulating cholesterol levels in an animal (e.g., a human).Type: GrantFiled: April 28, 2004Date of Patent: August 31, 2010Assignees: Xenon Pharmaceuticals, Inc., Univ. of British ColumbiaInventors: Michael R. Hayden, Angela R. Brooks-Wilson, Simon N. Pimstone
-
Patent number: 7785888Abstract: Recombinant viral vectors, especially parvovirus vectors such as adeno-associated virus (AAV) vectors, capable of enhanced expression of heterologous sequences, and methods for their construction and use, are provided. The vectors have a structure, or are capable of rapidly adopting a structure, which involves intrastrand base pairing of at least one region in a heterologous sequence.Type: GrantFiled: September 1, 2006Date of Patent: August 31, 2010Assignee: Genzyme CorporationInventor: Barrie J. Carter
-
Patent number: 7785887Abstract: Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.Type: GrantFiled: September 24, 2003Date of Patent: August 31, 2010Assignee: Onyx Pharmaceuticals, Inc.Inventors: Yuqiao Shen, Julie Nye, Terry Hermiston
-
Patent number: 7781208Abstract: A method for producing viral gene delivery vehicles which can be transferred to pre-selected cell types by using targeting conjugates. The gene delivery vehicles comprise: 1) the gene of interest; and 2) a viral capsid or envelope carrying a member of a specific binding pair, the counterpart of which is not directly associated with the surface of the target cell. These vehicles can be rendered unable to bind to their natural cell receptor. The targeting conjugates include the counterpart member of the specific binding pair, linked to a targeting moiety which is a cell-type specific ligand (or fragments thereof). The number of the specific binding pair present on the viral vehicles can be, for example, an immunoglobulin binding moiety (e.g., capable of binding to a Fc fragment, protein A, protein G, FcR or an anti-Ig antibody), or biotin, avidin or streptavidin. The virus' outer membrane or capsid may contain a substance which mediates entrance of the gene delivery vehicle into the target cell.Type: GrantFiled: February 7, 2006Date of Patent: August 24, 2010Assignee: Crucell Holland B.V.Inventors: Domenico Valerio, Victor W. Van Beusechem
-
Publication number: 20100209974Abstract: The present inventors succeeded in producing non-replicating SeV vectors whose genomic RNAs lack all genes for the NP, P, and L proteins, which are RNP-constituting proteins. The present inventors confirmed that the NP/P/L-deficient SeV vectors carrying a marker gene such as GFP provide high productivity, and high transfer and expression efficiencies of foreign genes (high MOI infection is essential for achieving high expression levels). By lacking the L gene or two or more of the NP, P, and L genes, the vectors of the present invention enable lowering the level of virus-derived proteins expressed in host cells, thereby reducing the immunogenicity upon in vivo administration.Type: ApplicationFiled: July 3, 2007Publication date: August 19, 2010Applicant: DNAVEC CorporationInventors: Jun You, Makoto Inoue, Mamoru Hasegawa
-
Publication number: 20100196336Abstract: Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.Type: ApplicationFiled: May 23, 2007Publication date: August 5, 2010Inventors: Dongsu Park, David Spencer, Natalia Lapteva
-
Patent number: 7749491Abstract: Agents and methods to alter rAAV transduction are provided.Type: GrantFiled: March 31, 2004Date of Patent: July 6, 2010Assignees: University of Iowa Research Foundation, Targeted Genetics CorporationInventors: John F. Engelhardt, Keith L. Munson, Ziying Yan
-
Patent number: 7745416Abstract: A method for regulating in vivo calcium transport in cardiac muscle of animals suffering from congestive heart failure is disclosed. According to the method, calcium ATPase activity (which decreases as congestive heart failure develops) and cardiac muscle contractility augmented by delivering a gene which operatively encodes the enzyme into the heart. Delivery systems, including but not limited to using adeno-associated viral vectors are provided. Methods for monitoring the expression and effect of the gene product on cardiac performance are also provided.Type: GrantFiled: January 13, 2003Date of Patent: June 29, 2010Assignee: The Regents of the University of CaliforniaInventors: Wolfgang H. Dillman, Frank Giordano, Ruben Mestril
-
Patent number: 7741039Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: GrantFiled: June 26, 2006Date of Patent: June 22, 2010Assignee: Merial SASInventors: Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
-
Publication number: 20100151576Abstract: The presently claimed subject matter provides conditionally replication competent adenoviral vectors that confer selective cytotoxicity on cells expressing HIF-1 by infecting cells that allow HIF-1 inducible promoters present within the vectors to function. Also provided are compositions and host cells based upon the vectors, as well as methods of propagating and using the vectors. The presently claimed subject matter further provides a method of inhibiting tumor growth by co-infecting cells in a tumor with a conditionally replication competent adenovirus vector in conjunction with a replication deficient adenovirus vector.Type: ApplicationFiled: February 19, 2010Publication date: June 17, 2010Inventors: Chuan-Yuan Li, Qian Huang, Mark W. Dewhirst
-
Publication number: 20100145015Abstract: The present invention relates to the microbial immunogens engineered to bear ?-gal epitope(s) for induction of potent humoral and cellular immune responses when administered to subjects having anti-Gal antibodies. In one embodiment, the present invention provides compositions and methods for propagating influenza virus in human, ape, Old World monkey or bird cells that have been engineered to express an ?1,3galactosyltransferase (? 1,3GT) gene to produce virions bearing hemagglutinin molecules containing ?-gal epitopes, to increase the immunogenicity of the influenza virus. In another embodiment, the present invention provides fusion proteins between influenza virus hemagglutinin and a microbial peptide or protein of interest, and enzymatic processing of this fusion protein to carry ?-gal epitopes, to increase the immunogenicity of the microbial peptide or protein of interest.Type: ApplicationFiled: March 26, 2008Publication date: June 10, 2010Inventor: Uri Galili
-
Publication number: 20100143304Abstract: Compositions and methods useful in transgene expression are provided. Herpes simplex virus type 1 thymidine kinase sequences (“TK sequences”) are used to enhance transgene expression in first generation and high capacity adenoviral vectors. An mCMV promoter-driven ?-galactosidase-expressing cassette is combined with TK sequences through direct fusion of the cDNA's. ?-galactosidase (transgene) expression is enhanced independent of adenoviral vector selection. Methods of enhancing transgene expression employing the inventive adenoviral vectors are provided, along with pharmaceutical preparations comprising the inventive vectors and kits for enhanced transgene expression.Type: ApplicationFiled: January 30, 2008Publication date: June 10, 2010Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Pedro R. Lowenstein, Maria Castro
-
Publication number: 20100136056Abstract: The present invention provides novel insertion sites for introducing DNA into pox vectors.Type: ApplicationFiled: December 16, 2009Publication date: June 3, 2010Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Dennis L. Panicali, Gail P. Mazzara, Linda R. Gritz, Patricia Greenhalgh
-
Publication number: 20100138944Abstract: Methods of avoiding repeat- and homology-induced silencing of transgenes are disclosed, in which transgene sequences are genetically altered to reduce the affects of gene silencing. FRET biosensors containing such genetic alterations for improved expression in cell lines and in vivo are disclosed.Type: ApplicationFiled: October 14, 2005Publication date: June 3, 2010Inventors: Wolf B Frommer, Karen Deuschle